Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis.

Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, Isaka K

The journal of obstetrics and gynaecology research26 May 2016Cited by 38 (Europe PMC)

PMID27225336DOI10.1111/jog.13023PepBankPUB-27225336

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postoperative endometriosis patients, recurrence did not differ significantly between goserelin and dienogest.
In plain wordsIn patients after endometriosis surgery, recurrence did not differ significantly between goserelin and dienogest.
Peptide
Goserelin
Outcome
No significant changePostoperative endometriosis recurrence versus dienogest
Study
n = 111
Comparator
Dienogest
Outcome group
Overall treatment effect · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
No significant difference was observed in the postoperative recurrence rate between the dienogest and goserelin groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55).
Summary · context
Patients were followed for 24 months after laparoscopic surgery.
Report a problemFND-2722533601
02HumanRandomized controlled trialSafety outcome
In postoperative endometriosis patients, side-effects were more marked with goserelin than dienogest.
In plain wordsIn patients after endometriosis surgery, side-effects were more marked with goserelin than dienogest.
Peptide
Goserelin
Outcome
IncreaseSide-effects
Study
n = 111
Comparator
Dienogest
Outcome group
Adverse events · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Side-effects were markedly observed in the goserelin group as compared with the dienogest group.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55).
Summary · context
Patients were followed for 24 months after laparoscopic surgery.
Report a problemFND-2722533605
03HumanNon-randomized trialEfficacy outcome
In postoperative endometriosis patients, menstrual pain significantly improved with goserelin.
In plain wordsIn patients after endometriosis surgery, menstrual pain improved significantly with goserelin.
Peptide
Goserelin
Outcome
DecreaseMenstrual pain
Study
n = 55
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Menstrual pain and chronic pelvic pain were significantly improved in both treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55).
Summary · context
Patients were followed for 24 months after laparoscopic surgery.
Report a problemFND-2722533603
04HumanNon-randomized trialEfficacy outcome
In postoperative endometriosis patients, chronic pelvic pain significantly improved with goserelin.
In plain wordsIn patients after endometriosis surgery, chronic pelvic pain improved significantly with goserelin.
Peptide
Goserelin
Outcome
DecreaseChronic pelvic pain
Study
n = 55
Outcome group
Pain · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
Menstrual pain and chronic pelvic pain were significantly improved in both treatment groups.
2 context sentences(design, population, supporting numbers)
Summary · context
A total of 111 patients were randomly assigned into two groups: the dienogest-administered group (n = 56) and the goserelin-administered group (n = 55).
Summary · context
Patients were followed for 24 months after laparoscopic surgery.
Report a problemFND-2722533604
05HumanNon-randomized trialEfficacy outcome
In postoperative endometriosis patients, recurrence did not differ significantly between goserelin and no treatment.
In plain wordsIn patients after endometriosis surgery, recurrence did not differ significantly between goserelin and no treatment.
Peptide
Goserelin
Outcome
No significant changePostoperative endometriosis recurrence versus no treatment
Study
n: not reported in source
Comparator
No postoperative treatment
Outcome group
Overall treatment effect · Reproductive and sexual health
Studied dose
Dose not stated
Source sentences
Summary
No significant difference was found in the recurrence rate between the goserelin group and non-treatment group;
Report a problemFND-2722533602

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)

Active, not recruitingPhase 4NCT06523530

Effect of a GnRH Analog on Hepatic Steatosis

Aristotle University Of Thessalonikin = 6226 Nov 2024 to est. Oct 2027

Metabolic Dysfunction-Associated Steatotic Liver Disease · Nonalcoholic Fatty Liver · Endometriosis

Trial page ClinicalTrials.govUpdated 23 Jul 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.